Robert B. Ford
At a glance: Robert B. Ford is CEO, Chair at Abbott Laboratories (ABT). Their latest SEC Form 4, filed Aug 27, 2026, reported a sale of $25.3M. On file: 1 purchase line ($2.0M) and 2 sale lines ($46.2M).
Disclosed holdings: about $54.4M of ABT stock: 522,664 shares (including shares held indirectly, e.g. through a trust or fund) reported on their latest Form 4 (filed Aug 27, 2026), valued at the Nov 20, 2026 close of $104.17. This counts only ABT shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
CEO, Chair at Abbott Laboratories (ABT)
Purchase track record
Not enough history. Based on 1 purchase with a full 90 days of price history.
Robert B. Ford's InsiderPrint
3 trades from SEC Form 4 filings, 2026 to 2026, drawn as one fingerprint.
Reading this print: Mostly sells, trading about 3 times a year, typically $20.9M a trade; often buys after the stock has fallen 15% or more.
- Bump outward: a purchase (1)
- Dent inward: a sale (2)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- David Baxley SpetzlerPresident · CAI · 98% match
- Sergey YezhkovSvp/Co-Head Of Global Business · EPAM · 96% match
- Eric J. DugasCFO · CLH · 95% match
- Susan Cohen LevyGeneral Counsel · NTRS · 95% match
- Vivek Ramaswamy10% Owner · ROIV · 94% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Every purchase since 2026
From the SEC's insider data sets: each open-market buy by Robert B. Ford, matched to how the stock did over the next 90 days against the S&P 500.
0 of 1 buy beat the S&P 500 (0%), median -27.2% vs. the index. Small sample: treat with care. All insider buys: 46%.
| Stock | Filed | 90 days vs. S&P 500 |
|---|---|---|
| ABT | Feb 6, 2026 | -27.2% |
Buys made close together in one stock count once. Price-only returns; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 27SEC | ABTAbbott Laboratories | Sell | 218,535486,758 held (−31%) | $115.57 | $25.3M | -9.9% |
| Aug 27SEC | ABTAbbott Laboratories | Sell | 180,297306,461 held (−37%) | $116.19 | $20.9M | -10.3% |
| Jan 26SEC | ABTAbbott LaboratoriesFirst buy | Buy | 18,800216,203 held (+10%) | $107.13 | $2.0M | -2.8% |
- Sell
CEO, Chair Robert B Ford sold $25.3M of ABT at $115.57 — cuts the stake by 31%.
- Sell
CEO, Chair Robert B Ford sold $20.9M of ABT at $116.19 — cuts the stake by 37%.
- Buy
CEO, Chair Robert B Ford bought $2.0M of ABT at $107.13 — first open-market purchase in our records.
Follow Robert B. Ford
Get one email when Robert B. Ford files a new purchase or sale. Free.
At most one email a day about Robert B. Ford, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.